Adult Vaccines Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

Adult Vaccines Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

The global adult vaccine market is expected to reach US$ 27.65 Billion by 2028, according to Renub Research. Vaccines are crucial for global public health, curbing infectious disease transmission, and potentially eradicating them. Numerous new vaccinations will become available in the near future, addressing diseases such as COVID-19, tuberculosis, malaria, HIV/AIDS, dengue fever, and other disorders. As therapeutic development progresses, it is important to broaden the definition of vaccines to include preventive injectable for conditions such as HIV, cardiometabolic disease, and common cancers.

The key force driving market expansion is the increased prevalence of infectious diseases worldwide. The prevalence of infectious diseases (such as influenza, hepatitis, and zoster) is rising; government campaigns to increase public awareness of immunization and government partnerships with biotechnology and pharmaceutical firms to develop new vaccines are all driving the adult vaccine market's expansion. Non-governmental organizations (NGOs), which are aggressively pushing adult vaccines, are also fueling the demand for adult immunizations. The participation of numerous NGOs throughout the course of the projected period is anticipated to contribute to a rise in the demand for adult vaccines worldwide. To achieve global immunization, the WHO and UNICEF issued guidelines for national vaccination programs.

Adult Vaccine Market is expected to exhibit a CAGR of 6.01% during 2022–2028.

Every year, at least 10 million deaths occur due to diseases that already have or will soon have adult vaccines and preventive injectable treatments available. These fatalities could be significantly reduced by implementing a comprehensive system of adult public-health interventions. With advancements in the development of preventive injectable and vaccines for various diseases, the existing infrastructure can be effectively utilized during non-pandemic periods. Implementing a global program for adult vaccination would ensure consistent and predictable demand for these vaccines and injectable therapies, which, in turn, could help offset the costs associated with expanding manufacturing capacity.

A number of game-changing vaccinations are currently in development. For example, the Centers for Disease Control and Prevention (CDC) issued new influenza vaccination schedules for adults in February 2022. Furthermore, according to the Australian Government Department of Health, the National Immunization Program (NIP) will cover influenza vaccinations for people who are most vulnerable to influenza virus infection beginning in June 2022. With the relaxation of worldwide and domestic public health restrictions resulting from the COVID-19 global pandemic, influenza is likely to resurface in the United States. Adult Vaccine Market was valued at US$ 19.48 Billion in 2022.

Within the adult vaccine sector, pneumococcal illness has emerged as the hazard with the quickest rate of growth.

By Vaccine Type, the adult vaccine market is divided into Influenza, HPV, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, Tdap, travel and misc, and varicella. The adult vaccination business has prioritized the development and distribution of potent vaccines due to pneumococcal disease's explosive expansion in the adult population. An older population, more awareness, government initiatives, advancements in vaccine cooperation, and technology within the healthcare sector are just a few of the reasons why the market for pneumococcal vaccines is growing exponentially. As long as this pattern persists, it is crucial to give vaccination efforts top priority and guarantee that everyone has access in order to shield adults from the catastrophic consequences of pneumococcal illness.

In the market for adult vaccines, India is now showing the fastest growth.

By Country, the adult vaccine market is broken up into North American countries (Canada, the United States), European countries (the United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland), Asian countries (India, China, Japan, Australia, South Korea), South American countries (Mexico, Brazil, Argentina), M.E.A. countries (Saudi Arabia, the UAE, South Africa), and the rest of the World. India's demand for adult immunizations is growing significantly due to its vast population and growing awareness of healthcare issues. There is a greater emphasis on adult immunization due to the rising burden of infectious illnesses and the necessity for preventive measures.

Adult vaccination campaigns and government measures have raised awareness and made vaccine access easier. Additionally, the distribution and accessibility of vaccines have been enhanced through improvements in healthcare infrastructure and the expansion of healthcare facilities. The increasing middle class, which has more disposable income, has also helped to make adult immunizations more accessible and more widely used.

Influenza-vaccinated populations will grow at a significant CAGR in the upcoming Years.

The Adult Vaccine Market is categorized by Vaccinated Population into Influenza, HPV, Zoster, MMR, Meningococcal, Pneumococcal, Hepatitis, Tdap, and Varicella. Influenza is still a significant public health problem that affects morbidity and death rates globally. Influenza kills between 290 and 650 thousand people annually and affects 5 to 10% of adults worldwide. The increased seasonal influenza incidence and rising vaccination recommendations have led to a positive market outlook for flu vaccines.

During the 2021–22 influenza seasons, approximately 9 million illnesses, 4 million medical visits, 10 thousand hospitalizations, and 5 thousand deaths were linked to influenza, according to the CDC. These figures demonstrate the critical necessity for preventative interventions like immunization. Governments play a critical role in monitoring demand and conducting vaccination programs globally to satisfy the unmet need for vaccination, working with organizations like the World Health Organization. The Manitoba government increased eligibility for the high-dose influenza vaccination to persons 65 and older in July 2022. This policy was designed to safeguard this age group from potentially lethal illnesses. As a result of such government measures, the worldwide influenza vaccine market is expanding.

Key Players

Key participants in the extremely competitive worldwide adult vaccination market include GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited. They are actively working to develop and market novel vaccines to meet the healthcare requirements of people globally. These industry giants play a critical role in influencing the adult immunization landscape and improving public health outcomes because to their significant market presence and commitment to research and development.

Renub Research latest report “Adult Vaccines Market Disease wise (Influenza, HPV, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, Tdap, travel and misc, and varicella) Numbers of Vaccinated Adults (Influenza, HPV, Zoster, MMR, Meningococcal, Pneumococcal, Hepatitis, Tdap, and Varicella), Country (Canada, the United States, Mexico, the United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Brazil, Argentina, Saudi Arabia, the UAE, South Africa, and the rest of the World), by company analysis (GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited)” provides a detailed analysis of Adult Vaccines Industry.

Disease wise – Adult Vaccine Market has been covered from 10 viewpoints

1. Influenza
2. HPV
3. Zoster
4. MMR
5. Pneumococcal
6. Meningococcal
7. Hepatitis
8. Tdap
9. Travel & Misc
10. Varicella

Disease wise – Numbers of Vaccinated Adults has been covered from 9 viewpoints

1. Influenza
2. HPV
3. Zoster
4. MMR
5. Pneumococcal
6. Meningococcal
7. Hepatitis
8. Tdap
9. Varicella

Country - Adult Vaccine Market has been covered from 21 viewpoints

1. North America

1.1 United States
1.2 Canada

2. Latin America

2.1 Mexico
2.2 Brazil
2.3 Argentina

3. Europe

3.1 United Kingdom
3.2 Germany
3.3 France
3.4 Russia
3.5 Italy
3.6 Spain
3.7 Switzerland

4. Asia Pacific

4.1 India
4.2 China
4.3 Japan
4.4 Australia
4.5 South Korea

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa

6. Rest of the World

All companies have been covered from 3 viewpoints:

• Oveview
• Recent Development
• Revenue

Company Analysis:

1. GlaxoSmithKline plc
2. AstraZeneca plc
3. Sanofi Pasteur
4. Pfizer Inc
5. CSL Limited